adjust ep exclud non-cash one-tim item
headquart foster citi ca one largest biotechnolog compani world
develop drug hepat hcv hiv oncolog
februari gilead report lower-than-expect result revenu revenu
ep compani guid product sale rang estim
ep miss increas dividend revenu line estim hep declin off-set
strength hiv sale ep miss driven higher-than-expect cog due excess raw materi
decreas demand hep drug compani guid higher-than-expect sg
driven increas expens car-t develop new product launch respect compani
also announc dividend increas reach dividend yield
hep hep gener revenu slightli lower expect hep cs declin
driven competit gener sale taken signific share
launch mavyret compani expect patient volum price stabil compani
guid hep sale estim
car-t yescarta gener sale also expect saw weak car-t
throughout competitor kymriah nv gener sale lower
forecast yescarta expect reach sale recent announc bcma
program termin impair charg profil competit
pipelin filgotinib addit readout believ one best profil
small molecul ra drug nash gild inhibitor selonsertib read
seen phii howev expect competit profil compani candid
new ceo gild newli hire ceo oday start march roch veteran expertis
global market life-cycle manag critic hiv hep franchis
rebuild growth believ done deal
maintain buy recommend share pmv estim per share
repres margin safeti current level expect investor favor deal add revenue-
gener asset rebuild growth believ buy like target
million except per share
exclud non-cash one-tim item
million except per share
hiv
current market discount pmv
after-tax payment buy option holder privat market valu
jing research analyst prepar report herebi certifi view express report accur reflect analyst person view subject
compani secur research analyst receiv direct indirect compens express specif recommend
view report
public data june buy
